Clarivate (NYSE:CLVT) Price Target Lowered to $2.60 at The Goldman Sachs Group

Posted by Brenda Bartman on Jul 30th, 2026

Clarivate (NYSE:CLVT – Get Free Report) had its price objective decreased by analysts at The Goldman Sachs Group from $2.90 to $2.60 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential upside of 30.33% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Barclays lowered their target price on Clarivate from $2.50 to $2.00 and set an “underweight” rating on the stock in a report on Thursday. Stifel Nicolaus cut their price target on Clarivate from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $3.07.

Read Our Latest Research Report on Clarivate

Clarivate Stock Performance

Shares of CLVT stock traded down $0.15 during trading hours on Thursday, reaching $2.00. 3,884,915 shares of the company’s stock were exchanged, compared to its average volume of 6,808,861. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.84 and a quick ratio of 0.84. The company’s 50 day moving average is $2.29 and its two-hundred day moving average is $2.43. The company has a market cap of $1.28 billion, a P/E ratio of -9.55 and a beta of 1.38. Clarivate has a 1 year low of $1.66 and a 1 year high of $4.55.

Clarivate (NYSE:CLVT – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.01. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The business had revenue of $587.30 million during the quarter, compared to the consensus estimate of $589.73 million. During the same quarter last year, the firm posted $0.18 EPS. The business’s revenue was down 5.5% compared to the same quarter last year. Equities research analysts anticipate that Clarivate will post 0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Clarivate

Institutional investors have recently modified their holdings of the company. Iridian Asset Management LLC CT raised its holdings in Clarivate by 52.4% in the 4th quarter. Iridian Asset Management LLC CT now owns 1,528,410 shares of the company’s stock valued at $5,105,000 after acquiring an additional 525,452 shares during the last quarter. KBC Group NV acquired a new stake in shares of Clarivate during the first quarter worth $4,118,000. BW Gestao de Investimentos Ltda. grew its position in shares of Clarivate by 51.7% in the fourth quarter. BW Gestao de Investimentos Ltda. now owns 4,345,321 shares of the company’s stock valued at $14,513,000 after purchasing an additional 1,480,300 shares during the period. LSV Asset Management increased its stake in Clarivate by 25.6% in the fourth quarter. LSV Asset Management now owns 2,647,900 shares of the company’s stock valued at $8,844,000 after purchasing an additional 540,400 shares during the last quarter. Finally, Invenomic Capital Management LP increased its stake in Clarivate by 3.8% in the fourth quarter. Invenomic Capital Management LP now owns 9,029,414 shares of the company’s stock valued at $30,158,000 after purchasing an additional 326,369 shares during the last quarter. Institutional investors and hedge funds own 85.72% of the company’s stock.

Clarivate News Roundup

Here are the key news stories impacting Clarivate this week:

Positive Sentiment: Adjusted earnings exceeded expectations. Clarivate reported second-quarter EPS of $0.19, above the $0.17-$0.18 analyst consensus and up from $0.18 a year earlier. Clarivate Reports Second Quarter 2026 Results
Positive Sentiment: Management reaffirmed its 2026 financial outlook and said its Value Creation Plan is advancing strategic priorities, improving the company’s financial profile and supporting a sharper focus following the planned Life Sciences & Healthcare divestiture. Clarivate Reports Second Quarter 2026 Results
Positive Sentiment: Stifel Nicolaus maintained a Buy rating and sees substantial potential upside, although it reduced its price target from $6 to $5. Clarivate Price Target Update
Neutral Sentiment: Clarivate appointed Michael Easton as executive vice president and CFO, effective August 8. Easton, a longtime company executive with more than 25 years of financial and operational experience, will replace Jonathan Collins, who is leaving to pursue another opportunity. Clarivate Appoints Michael Easton as Chief Financial Officer
Negative Sentiment: Revenue was weaker than expected and declined year over year. Quarterly revenue of $587.3 million missed the approximately $589.7 million consensus estimate and fell 5.5% from the prior-year period. Clarivate also reported a negative net margin, underscoring ongoing concerns about growth and profitability. Clarivate Q2 Earnings and Revenues
Negative Sentiment: The lower Stifel price target signals reduced near-term expectations despite the continued Buy rating, adding pressure to the investment case.

Clarivate Company Profile

(Get Free Report)

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.